Menu
← Oncology Approval Tracker
FDA DECISION ·
Zirabev + chemotherapy
bevacizumab-bvzr with indication-specific chemotherapy · Pfizer
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adds use in stage III or IV epithelial ovarian, fallopian tube or primary peritoneal cancer after initial surgery with carboplatin and paclitaxel, then single-agent maintenance. Also adds specified chemotherapy combinations for platinum-sensitive recurrence and platinum-resistant recurrence after no more than two prior chemotherapy regimens.
LAMPGEN ANALYSIS
Why it matters
This extends the biosimilar label to several gynecologic cancer settings with different treatment backbones.
What research teams should watch
Verify surgical timing, platinum sensitivity, prior chemotherapy and the regimen listed for the applicable setting.
PRIMARY RECORDS